ClinicalTrials.gg
RecruitingNCT07438496GARDENIA-SLEUpdated Nov 3, 2026

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

A Phase 3 interventional study of Nipocalimab and Placebo in Lupus Erythematosus, Systemic, sponsored by Janssen Research & Development, LLC. Recruiting at 272 sites in 33 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026First site in MexicoSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson — 1 open to participants now, 1 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Johnson & Johnson.

Started
2026
the only one that year
Phase 3
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson, this one is the only one that started in 2026, is one of 3 in phase 3, and was the 10th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).

03

Conditions studied

  • Lupus Erythematosus, Systemic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:-

  • Medically stable on the basis of physical examination, medical history, vital signs and 12-lead (ECG) performed at screening
  • Clinical diagnosis of systemic lupus erythematosus (SLE) for more than or equal to (>=) 24 weeks prior to screening and meeting european league against rheumatism/american college of rheumatology (EULAR/ACR) classification criteria
  • Must have a systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score >= 6 and a clinical SLEDAI-2K >= 4 at screening, AND a clinical SLEDAI-2K score >= 4 points at Week 0. For eligibility, points attributed to "lupus headache," "alopecia," and "organic brain syndrome" are excluded
  • Participants of must have a negative serum beta human chorionic gonadotropin (β-hCG) test at screening and a negative urine (β- hCG) test at Week 0 prior to randomization
  • Has at least 1 BILAG-2004 A score or 2 BILAG-2004 B scores observed at screening

Exclusion Criteria:

  • History of severe, progressive and/or uncontrolled hepatic, gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension, and/or any other medical or uncontrolled disorder (s) or abnormalities in screening laboratory
  • Any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications
  • Confirmed or suspected clinical immunodeficiency syndrome not related to treatment of SLE or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Has shown a previous severe immediate reaction, such as anaphylaxis, to therapeutic proteins
  • Suspected or known allergies, hypersensitivity, or intolerance to nipocalimab or its , or excipients used in the placebo formulation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Nipocalimab

    Participants will receive nipocalimab up to Week 52 in the double blind treatment period along with standard of care treatments. At Week 52, eligible participants from both studies will have the option to enter an open-label long-term extension (OLE) period, where they will continue to receive nipocalimab until Week 156 or until the study intervention is discontinued.

    Drug: Nipocalimab · Drug: Standard of care treatment

  • Placebo comparator
    Placebo

    Participants will receive placebo up to Week 52 in the double blind treatment period along with standard of care treatment. At Week 52, eligible participants from both studies will have the option to enter an OLE period, where they will continue to receive nipocalimab until Week 156 or until the study intervention is discontinued.

    Drug: Nipocalimab · Drug: Placebo · Drug: Standard of care treatment

Interventions

  • Nipocalimab will be administered.

  • DrugPlacebo

    Placebo will be administered.

  • DrugStandard of care treatment

    Protocol-defined topical and systemic standard of care background treatments.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 52

    SLE SRI-4 composite response is a composite response of at least a 4 point reduction in SLE Disease Activity Index 2000 (SLEDAI-2K), no British Isles Lupus Assessment Group-2004 (BILAG-2004) worsening, defined as no new A or less than or equal to \<= 1 new B items compared to baseline, no worsening in Physician's Global Assessment (PGA \[greater than {\>} 10 percent {%} increase from baseline\]).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving SRI-4 Composite Response at Week 52 with High Baseline IFN Gene Signature (Interferon [IFN] high)

    SLE SRI-4 composite response is a composite response of at least a 4 point reduction in SLEDAI-2K, no BILAG-2004 worsening, defined as no new A or \<= 1 new B items compared to baseline, no worsening in PGA (\> 10% increase from baseline). IFN high is defined as elevated peripheral type 1 IFN gene signature at baseline.

    Time frame: Week 52

  2. Percentage of Participants Achieving SRI-4 Composite Response at Week 52 with Sustained Reduction in Oral Glucocorticoid (GC) Dose

    SLE SRI-4 composite response is a composite response of at least a 4 point reduction in SLEDAI-2K, no BILAG-2004 worsening, defined as no new A or \<= 1 new B items compared to baseline, no worsening in PGA (\> 10% increase from baseline). Sustained reduction in oral GC dose at Week 52 is defined as achieving \<= 5 mg/day oral prednisone (or equivalent) AND no increase of that dose from Week 32 through Week 52.

    Time frame: Week 52

  3. Percentage of Participants Who Achieve Lupus Low Disease Activity State (LLDAS) At Week 52

    LLDAS is defined as follows: SLEDAI-2K \<= 4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity measured as maintaining a D (no disease activity but suggests the system had previously been affected) or E (no current or previous disease activity) score in BILAG gastrointestinal body system, no new lupus disease activity compared with the previous assessment measured as no new or worsening individual BILAG parameters, physician's global assessment of disease activity \<= 1 on a 3-point visual analog scale from no disease activity to severe disease activity, a current prednisolone (or equivalent) dose \<= 7.5 milligram (mg) daily and well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.

    Time frame: Week 52

  4. Percentage of Participants with < 2 Active Joints at Week 52 in Participants with >= 2 Active Joints at Baseline

    Percentage of participants with \< 2 active joints at Week 52 in participants with \>= 2 active joints at baseline will be reported.

    Time frame: Week 52

  5. Change From Baseline in Lupus Symptoms Joint Pain Score at Week 52

    Lupus symptoms joint pain score at Week 52 will be reported.

    Time frame: Baseline, Week 52

  6. Percentage of Participants Achieving Sustained Reduction in Oral GC Dose at Week 52 in Participants Treated with Oral GC >5 mg/Day Prednisone (or equivalent) at Baseline

    Percentage of participants achieving sustained reduction in oral GC dose at Week 52 in participants treated with oral GC \>5 mg/Day prednisone (or equivalent) at baseline will be reported.

    Time frame: Week 52

  7. Change from Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT) Fatigue Score at Week 52

    FACIT-Fatigue version 4.0 is a 13-item questionnaire that assesses participant-reported fatigue and its impact upon daily activities and function over the past 7 days. Participants will be asked to answer each question using a 5-point Likert scale (0=Not at all; 1=A little bit; 2=Somewhat; 3=Quite a bit; and 4=Very much). FACIT-Fatigue has a total score range from 0 to 52, with 0 being the worst possible score and 52 the best.

    Time frame: Baseline, Week 52

  8. Percentage of Participants With BILAG Flare Free Status Through Week 52

    A participant has a flare-free status if no flare has been reported during the 52-week treatment period. A flare was defined as either 1 or more new BILAG-2004 A (severe disease activity) or 2 or more new BILAG-2004 B (moderate disease activity) items compared to the previous visit.

    Time frame: Up to Week 52

  9. Percentage of Participants Achieving SRI-4 Composite Response at Week 52 with High Baseline Autoantibodies (Autoantibody High)

    SLE SRI-4 composite response is a composite response of at least a 4 point reduction in SLEDAI-2K, no BILAG-2004 worsening, defined as no new A or \<= 1 new B items compared to baseline, no worsening in PGA (\> 10% increase from baseline). Autoantibody high participants is defined as participants with high autoantibody at baseline.

    Time frame: Week 52

07

Study locations

270 of 272 sites recruiting

Showing the first 100 of 272 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Dec 6, 2028
CompletionEst.
Nov 7, 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added, 1 site removed — first site in Mexico. Floridian Clinical Research LLC is now Completed
Show 24 added (6 Mexico, 5 United States, 3 Georgia, 3 Serbia, 2 China, 2 South Africa, 1 Switzerland, 1 Turkey (Türkiye), 1 Norway)
  • Denver Arthritis Clinic · Denver, United States
  • Amarillo Medical Specialists Rheumatology · Amarillo, United States
  • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
  • TSMU The First University Clinic · Tbilisi, Georgia
  • Clinic on Mtskheta Street · Tbilisi, Georgia
  • Caucasus Medical Centre · Tbilisi, Georgia
  • Institute Of Rheumatology 1 · Belgrade, Serbia
  • Institute of Rheumatology · Belgrade, Serbia
  • Hopitaux Universitaires de Geneve - HUG · Geneva, Switzerland
  • Izmir Ataturk Egitim ve Arastirma Hastanesi · Izmir, Turkey (Türkiye)
  • Providence Medical Foundation · Mission Viejo, United States
  • Morehouse School of Medicine · Atlanta, United States
  • Oklahoma Medical Research Foundation · Oklahoma City, United States
  • Investigación y Biomedicina de Chihuahua · Chihuahua City, Mexico
  • Centro Medico del Angel · Mexicali, Mexico
  • RM Pharma Specialists · Mexico City, Mexico
  • Medical Care & Research SA de CV · Mérida, Mexico
  • Hospital SMIQ · Querétaro, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi · San Luis Potosí City, Mexico
  • Universitetssykehuset Nord-Norge HF · Tromsø, Norway
  • Institute Of Rheumatology 2 · Belgrade, Serbia
  • Clinical Trials Network Helderberg · Cape Town, South Africa
  • Netcare Umhlanga Medical Centre · Umhlanga, South Africa
Show 1 removed
  • Providence Medical Foundation · Fullerton, United States
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    13 sites added, 1 site removed — first site in Mexico. Floridian Clinical Research LLC is now Completed
    Show 13 added (6 Mexico, 3 United States, 2 South Africa, 1 Norway, 1 Serbia)
    • Providence Medical Foundation · Mission Viejo, United States
    • Morehouse School of Medicine · Atlanta, United States
    • Oklahoma Medical Research Foundation · Oklahoma City, United States
    • Investigación y Biomedicina de Chihuahua · Chihuahua City, Mexico
    • Centro Medico del Angel · Mexicali, Mexico
    • RM Pharma Specialists · Mexico City, Mexico
    • Medical Care & Research SA de CV · Mérida, Mexico
    • Hospital SMIQ · Querétaro, Mexico
    • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi · San Luis Potosí City, Mexico
    • Universitetssykehuset Nord-Norge HF · Tromsø, Norway
    • Institute Of Rheumatology 2 · Belgrade, Serbia
    • Clinical Trials Network Helderberg · Cape Town, South Africa
    • Netcare Umhlanga Medical Centre · Umhlanga, South Africa
    Show 1 removed
    • Providence Medical Foundation · Fullerton, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    11 sites added
    Show 11 added (3 Georgia, 2 United States, 2 China, 2 Serbia, 1 Switzerland, 1 Turkey (Türkiye))
    • Denver Arthritis Clinic · Denver, United States
    • Amarillo Medical Specialists Rheumatology · Amarillo, United States
    • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    • TSMU The First University Clinic · Tbilisi, Georgia
    • Clinic on Mtskheta Street · Tbilisi, Georgia
    • Caucasus Medical Centre · Tbilisi, Georgia
    • Institute Of Rheumatology 1 · Belgrade, Serbia
    • Institute of Rheumatology · Belgrade, Serbia
    • Hopitaux Universitaires de Geneve - HUG · Geneva, Switzerland
    • Izmir Ataturk Egitim ve Arastirma Hastanesi · Izmir, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07438496
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 5, 2026
Primary completion
Dec 6, 2028 (estimated)
Completion
Nov 7, 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion